-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, "large and small chain reorganization and mergers and acquisitions" have been staged in the pharmacy industry
.
For example, in the past 2021, the "big-handed" mergers and acquisitions of leading chain chains have continued one after another.
Whether it was the common people, Yixintang, and Yifeng who were listed earlier, or Dashenlin, Jianzhijia, and Shuyu commoners who entered the capital market.
All obviously regard mergers and acquisitions as an important measure for the company to expand its territory
.
According to incomplete statistics, as of the third quarter of 2021, the number of stores in the four major listed chains, Yixintang, Dashenlin, Common People, and Yifeng Pharmacy, has exceeded 7,000
.
Among them, the number of Yixintang and ordinary people's stores has reached more than 8,000
.
In addition, data shows that from 2011 to the first half of 2021, the number of pharmacies in China increased from 424,000 to 579,000, an increase of 36.
56%; the number of chain stores increased from 147,000 to 329,600, An increase of 124.
01%, the chain rate increased from 34.
67% to 56.
93%
.
The analysis believes that behind the continuous expansion of the head chain and the continuous increase of the pharmacy chain rate, it is actually the result that the industry competition is becoming increasingly fierce, and the small and medium-sized enterprises are facing the competitive pressure from the giants and are accelerating their withdrawal
.
It is understood that in recent years, with the impact of drug price cuts and volume purchases, the passenger flow and profits of the pharmacy industry have been declining, and the competition has become increasingly fierce
.
Therefore, under the background that the pharmacy industry has entered the "stock competition", in order to further expand the head chain, it has become a general trend to acquire other pharmacies
.
It is worth mentioning that the industry expects that in the future, chain pharmacies will continue to intensify mergers and acquisitions to further increase market share, and the industry market concentration will also accelerate
.
This conclusion is mainly due to the fact that on October 28, 2021, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period", proposing requirements that will increase the concentration of the industry
.
Among them, the opinions clearly stated that by 2025, 5-10 specialized and diversified pharmaceutical retail chain enterprises with a value of over 50 billion yuan should be cultivated.
The annual sales of the top 100 pharmaceutical retail enterprises should account for more than 65% of the total pharmaceutical retail market.
The linkage rate is close to 70%
.
In this regard, the industry generally believes that with the help of this policy, the competition in the pharmaceutical retail market will become more intense in the future, the trend of expansion of large chain pharmacies will continue to accelerate, and more small and medium-sized pharmacies in the industry will also be accelerated.
or mergers
.
In fact, according to the author's understanding, at the beginning of this year, a number of small and medium-sized pharmacies have quietly withdrawn
.
For example, on January 4, the website of the Haikou Market Supervision and Administration Bureau released an announcement on the cancellation of the "Drug Business License" of 38 pharmaceutical retail enterprises including the Penghui Plaza Branch of Hainan Qizhengtang Pharmaceutical Chain Operation Co.
,
Ltd.
In addition, on January 7, the Liaoyang Municipal Bureau of Supervision also issued an announcement stating that in accordance with the relevant provisions of the Drug Administration Law and the Measures for the Administration of Pharmaceutical Business Licenses, Liaoyang Tianzheng Pharmaceutical Co.
, Ltd.
Tianshui Chunguang Store and Liaoyang Tianzheng Pharmaceutical Co.
, Ltd.
The "Drug Business License" of Lingchun Tong Pharmacy shall be cancelled
.
.
For example, in the past 2021, the "big-handed" mergers and acquisitions of leading chain chains have continued one after another.
Whether it was the common people, Yixintang, and Yifeng who were listed earlier, or Dashenlin, Jianzhijia, and Shuyu commoners who entered the capital market.
All obviously regard mergers and acquisitions as an important measure for the company to expand its territory
.
According to incomplete statistics, as of the third quarter of 2021, the number of stores in the four major listed chains, Yixintang, Dashenlin, Common People, and Yifeng Pharmacy, has exceeded 7,000
.
Among them, the number of Yixintang and ordinary people's stores has reached more than 8,000
.
In addition, data shows that from 2011 to the first half of 2021, the number of pharmacies in China increased from 424,000 to 579,000, an increase of 36.
56%; the number of chain stores increased from 147,000 to 329,600, An increase of 124.
01%, the chain rate increased from 34.
67% to 56.
93%
.
The analysis believes that behind the continuous expansion of the head chain and the continuous increase of the pharmacy chain rate, it is actually the result that the industry competition is becoming increasingly fierce, and the small and medium-sized enterprises are facing the competitive pressure from the giants and are accelerating their withdrawal
.
It is understood that in recent years, with the impact of drug price cuts and volume purchases, the passenger flow and profits of the pharmacy industry have been declining, and the competition has become increasingly fierce
.
Therefore, under the background that the pharmacy industry has entered the "stock competition", in order to further expand the head chain, it has become a general trend to acquire other pharmacies
.
It is worth mentioning that the industry expects that in the future, chain pharmacies will continue to intensify mergers and acquisitions to further increase market share, and the industry market concentration will also accelerate
.
This conclusion is mainly due to the fact that on October 28, 2021, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period", proposing requirements that will increase the concentration of the industry
.
Among them, the opinions clearly stated that by 2025, 5-10 specialized and diversified pharmaceutical retail chain enterprises with a value of over 50 billion yuan should be cultivated.
The annual sales of the top 100 pharmaceutical retail enterprises should account for more than 65% of the total pharmaceutical retail market.
The linkage rate is close to 70%
.
In this regard, the industry generally believes that with the help of this policy, the competition in the pharmaceutical retail market will become more intense in the future, the trend of expansion of large chain pharmacies will continue to accelerate, and more small and medium-sized pharmacies in the industry will also be accelerated.
or mergers
.
In fact, according to the author's understanding, at the beginning of this year, a number of small and medium-sized pharmacies have quietly withdrawn
.
For example, on January 4, the website of the Haikou Market Supervision and Administration Bureau released an announcement on the cancellation of the "Drug Business License" of 38 pharmaceutical retail enterprises including the Penghui Plaza Branch of Hainan Qizhengtang Pharmaceutical Chain Operation Co.
,
Ltd.
In addition, on January 7, the Liaoyang Municipal Bureau of Supervision also issued an announcement stating that in accordance with the relevant provisions of the Drug Administration Law and the Measures for the Administration of Pharmaceutical Business Licenses, Liaoyang Tianzheng Pharmaceutical Co.
, Ltd.
Tianshui Chunguang Store and Liaoyang Tianzheng Pharmaceutical Co.
, Ltd.
The "Drug Business License" of Lingchun Tong Pharmacy shall be cancelled
.
